Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
The rate of on-treatment deaths was 17.1% in the venetoclax arm and 3.3% in the control arm.
After physicians voiced concerns about an active surveillance recommendation, the NCCN panel revised the guidelines.
Survey responses revealed a lack of culturally competent care and tailored resources.
There was an improvement in progression-free survival despite crossover.
The phase 3 CanStem111P study was terminated early due to futility.
The presence of ctDNA, both at baseline and after treatment, was associated with worse survival outcomes.
Most vaccinated patients reported having mild side effects or none at all.
